By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Madrigal Pharmaceuticals 

500 Office Center Drive
Suite 400
Fort Washington  Pennsylvania  19034  U.S.A.
Phone: 267-327-4445 Fax:


SEARCH JOBS


Industry
Pharmaceutical






Company News
Madrigal Reports Third Quarter 2016 Financial Results 11/15/2016 10:45:06 AM
Madrigal Announces The Initiation Of A Phase 2 Study Of MGL-3196 In Patients With Non-Alcoholic Steatohepatitis (NASH) 10/20/2016 12:15:30 PM
Madrigal Announces The Initiation Of A Phase II Study Of MGL-3196 In Patients With Non-Alcoholic Steatohepatitis (NASH) 10/20/2016 8:13:19 AM
Madrigal Wrangles Cancer Deal Worth $163 Million+ Out of Massachusetts' Tarveda 9/19/2016 5:57:16 AM
Synta (SNTA) Announces Date And Location Of Annual Meeting Of Stockholders To Vote On Merger With Madrigal 6/9/2016 10:45:13 AM
After Exploring Strategic Alternatives, Synta (SNTA) Agrees to Merge with Madrigal to Create Leading Cardio-Metabolic Diseases and NASH Company 4/14/2016 5:57:13 AM
Madrigal Pharmaceuticals Announces Results From MGL-3196 Multiple Dose Study at the American Heart Association 2012 Scientific Sessions 11/7/2012 8:13:47 AM
Madrigal Pharmaceuticals Launches Multiple Dose Phase I Clinical Study for 3196 in Dyslipidemia 3/5/2012 8:24:54 AM
//-->